Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant

NCT04044560 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Stopped Slow enrolment, loss of funding

Conditions

B-cell Adult Acute Lymphoblastic Leukemia
Stem Cell Leukemia
Minimal Residual Disease

Interventions

BIOLOGICAL: blinatumomab

Sponsor

University of British Columbia

Collaborators

[object Object]